1. Efficacy and potential benefits of intermittent versus continuous androgen deprivation therapy
The ICELAND study, a multicentre phase 3 randomised study was conducted in 20 European countries, investigated the efficacy and safety profile of intermittent androgen deprivation (IAD) compared with continuous androgen deprivation (CAD) therapy in patients with non-metastatic prostate cancer. 700 patients were randomly assigned to either IAD or CAD therapy with leuprorelin acetate. Leuprorelin is also called Prostap or Lutrate and is a type of hormone therapy for prostate cancer.
Results from this study indicate no statistically significant or clinically relevant difference between the IAD or CAD groups for time to PSA progression, PSA progression free survival and mean PSA levels over time or quality of life in patients with non-metastatic locally advanced or relapsing prostate cancer.
The authors concluded the main potential benefit of IAD compared with CAD was reduced drug costs with comparable overall survival rates.